Stockreport

CSL Behring's Gene Therapy HEMGENIX® (etranacogene dezaparvovec-drlb) Four Years Post-Infusion Data Continue to Show Sustained Efficacy and Safety in Adults with Hemophilia B [Yahoo! Finan...

CSL LTD SP/ADR  (CSLLY) 
NASDAQ:AMEX Investor Relations: csl.com/investors
PDF PR Newswire Fri, February 7, 2025 at 3:12 PM GMT+1 10 min read In This Article CMXHF CSLLY QURE 94 percent of patients eliminated factor IX prophylaxis an [Read more]